Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?

Bone Marrow Transplantation volume 48, pages 1489–1496 (2013)Cite this article

Subjects

Abstract

Modern chemoimmunotherapies have produced higher response rates and improved survival in mantle cell lymphoma (MCL); however, disease relapse remains a challenge. The availability of various post-remission maintenance or consolidation strategies, have led some to question the role of upfront autologous hematopoietic cell transplantation (auto-HCT) consolidation for MCL, in the chemoimmunotherapy-era. A one size fits all approach is no longer appropriate for MCL in first remission, and the choice of preferred post-remission (observation, maintenance or consolidation) strategy is increasingly becoming a factor of patient age, comorbidities and disease risk stratification. In select low-risk patients (based on Mantle cell lymphoma International Prognostic Index (MIPI)), observation following rituximab plus Hyper-CVAD-like inductions seems appropriate. Rituximab maintenance after anthracycline-based chemoimmunotherapies in elderly transplant ineligible patients has shown survival benefit and should be considered a valid option. Limited studies suggest feasibility of radioimmunotherapy consolidation in first remission; however, in the absence of randomized data, this modality remains investigational. In younger, transplant-eligible patients receiving cytarabine-containing inductions, upfront consolidation with auto-HCT has shown survival benefit, and remains a standard-of-care option in the modern-era. Hyper-CVAD associated stem cell mobilization failure is an increasingly recognized problem, underscoring the need for alternative inductions, or consideration for early stem cell collection, when this induction regimen is used. Outcomes of high-risk MIPI patients remain suboptimal with currently available induction and post-remission strategies and represents an area where adoptive immunotherapy in the form of allogeneic-HCT warrants investigation. Incorporation of novel MoAbs and targeted agents (PI3K inhibitors, mTOR inhibitors, BTK inhibitors and so on.) in maintenance and consolidation strategies will build on the significant therapeutic gains of last decade, in coming years.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Armitage JO . Management of mantle cell lymphoma. Oncology (Williston Park) 1998; 12: 49–55.

    CAS  Google Scholar 

  2. Dreyling M, Hiddemann W, European MCL Network. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009; 2009: 542–551.

    Article  Google Scholar 

  3. Armitage JO, Weisenburger DD . New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795.

    Article  CAS  Google Scholar 

  4. Fisher RI . Mantle-cell lymphoma: classification and therapeutic implications. Ann Oncol 1996; 7 (Suppl 6): S35–S39.

    Article  Google Scholar 

  5. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150: 200–208.

    CAS  PubMed  Google Scholar 

  6. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27: 6101–6108.

    Article  CAS  Google Scholar 

  7. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677–2684.

    Article  CAS  Google Scholar 

  8. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687–2693.

    Article  CAS  Google Scholar 

  9. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511–518.

    Article  Google Scholar 

  10. Weisenburger DD, Vose JM, Greiner TC, Lynch JC, Chan WC, Bierman PJ et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000; 64: 190–196.

    Article  CAS  Google Scholar 

  11. Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355–362.

    Article  CAS  Google Scholar 

  12. Martin P, Smith M, Till B . Management of mantle cell lymphoma in the elderly. Best Pract Res Clin Haematol 2012; 25: 221–231.

    Article  Google Scholar 

  13. Vose JM . Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2012; 87: 604–609.

    Article  Google Scholar 

  14. Ott G, Kalla J, Ott MM, Schryen B, Katzenberger T, Muller JG et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 1997; 89: 1421–1429.

    CAS  PubMed  Google Scholar 

  15. Schaffel R, Hedvat CV, Teruya-Feldstein J, Persky D, Maragulia J, Lin D et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010; 21: 133–139.

    Article  CAS  Google Scholar 

  16. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185–197.

    Article  CAS  Google Scholar 

  17. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115: 2630–2639.

    Article  CAS  Google Scholar 

  18. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558–565.

    Article  CAS  Google Scholar 

  19. Geisler CH, Kolstad A, Laurell A, Raty R, Jerkeman M, Eriksson M et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115: 1530–1533.

    Article  CAS  Google Scholar 

  20. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.

    Article  CAS  Google Scholar 

  21. Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288–1294.

    Article  CAS  Google Scholar 

  22. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984–1992.

    Article  CAS  Google Scholar 

  23. Epner E, Unger J, Miller T, Rimzsa L, Spier C, Leblanc M et al. A multi center trial of hyperCVAD+Rituxan in patients with newly diagnosed mantle cell lymphoma. Blood 2007; 110: 387.

    Google Scholar 

  24. Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156: 346–353.

    Article  CAS  Google Scholar 

  25. Rummel M, Niederle N, Maschmeyer G, Banat A, von Gruenhagen U, Losem C et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. J Clin Oncol, (ASCO Meeting Abstracts) 2012; 30: 3.

    Article  Google Scholar 

  26. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42–51.

    Article  CAS  Google Scholar 

  27. Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009; 27: 1607–1614.

    Article  CAS  Google Scholar 

  28. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005; 16: 1675–1682.

    Article  CAS  Google Scholar 

  29. Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17: 1418–1423.

    Article  CAS  Google Scholar 

  30. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520–531.

    Article  CAS  Google Scholar 

  31. Vitolo U, Ladetto M, Boccomini C, Evangelista A, Gamba E, Russo E et al. Brief chemoimmunotherapy R-FND with rituximab consolidation followed by randomization between rituximab maintenance vs observation as first line treatment in elderly patients with advanced follicular lymphoma (FL): final results of a prospective randomized trial by italian lymphoma foundation (FIL). Blood 2011; 118: 777.

    Google Scholar 

  32. Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009; 20: 520–525.

    Article  CAS  Google Scholar 

  33. Kahl B, Li H, Smith M, Gascoyne R, Yang T, Paietta E et al. Mature results from ECOG study E1405 - a phase II study of VcR-CVAD with maintenance rituximab for rreviously untreated mantle cell lymphoma. Blood, (ASH Annual Meeting Abstracts) 2012; 120: 153.

    Google Scholar 

  34. Dunleavy K, Grant C, Hessler J, Miller B, Steinberg S, Pittaluga S et al. Bortezomib+DA-EPOCH-R induction therapy followed by maintenance bortezomib versus observation in newly diagnosed mantle cell lymphoma. Blood, (ASH Annual Meeting Abstracts) 2012; 120: 3672.

    Google Scholar 

  35. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156–5164.

    Article  CAS  Google Scholar 

  36. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006; 24: 4143–4149.

    Article  CAS  Google Scholar 

  37. Skarbnik AP, Smith MR . Radioimmunotherapy in mantle cell lymphoma. Best Pract Res Clin Haematol 2012; 25: 201–210.

    Article  Google Scholar 

  38. Zelenetz AD, Noy A, Pandit-Taskar N, Scordo M, Rijo I, Zhou Y et al. Sequential radioimmunotherapy with tositumomab/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. J Clin Oncol, (ASCO Meeting Abstracts) 2006; 24: 7560.

    Google Scholar 

  39. Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012; 30: 3119–3126.

    Article  CAS  Google Scholar 

  40. Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257–262.

    Article  CAS  Google Scholar 

  41. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, Lopez-Guillermo A, Gisselbrecht C et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793–800.

    Article  Google Scholar 

  42. Vose J, Loberiza R, Bierman J, Armitage O . The addition of stem cell transplantation following induction chemotherapy improves overall survival in mantle cell lymphoma patients who achieve a complete response. Haematologica 2012; 97: 100–101.

    Google Scholar 

  43. Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): a phase II study from the GELA. Blood 2012; 121: 48–53.

    Article  Google Scholar 

  44. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144–4152.

    Article  CAS  Google Scholar 

  45. Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net). Blood, (ASH Annual Meeting Abstracts) 2012; 120: 151.

    Google Scholar 

  46. Arne K, Laurell A, Jerkeman M, Gronbaek K, Elonen E, Raty R et al. Nordic MCL3 study: zevalin combined with high-dose chemotherapy followed by autologous stem cell support as late intensification for mantle cell lymphoma (MCL) patients<66 years not in CR after induction chemoimmunotherapy: no benefit of zevalin. Blood, (ASH Annual Meeting Abstracts) 2012; 120: 747.

    Google Scholar 

  47. Andersen NS, Pedersen L, Elonen E, Johnson A, Kolstad A, Franssila K et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 2003; 71: 73–80.

    Article  Google Scholar 

  48. Hamadani M . Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? Bone Marrow Transplant 2012; 48: 1013–1021.

    Article  Google Scholar 

  49. Hill BT, Rybicki L, Smith S, Dean R, Kalaycio M, Pohlman B et al. Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. Leuk Lymphoma 2011; 52: 986–993.

    Article  CAS  Google Scholar 

  50. Majhail NS, Bajorunaite R, Lazarus HM, Wang Z, Klein JP, Zhang MJ et al. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Br J Haematol 2009; 147: 129–139.

    Article  Google Scholar 

  51. Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 2011; 29: 3023–3029.

    Article  Google Scholar 

  52. Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 690–697.

    Article  CAS  Google Scholar 

  53. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol 2009; 27: 4767–4773.

    Article  CAS  Google Scholar 

  54. Jantunen E, Canals C, Attal M, Thomson K, Milpied N, Buzyn A et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2012; 23: 166–171.

    Article  CAS  Google Scholar 

  55. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3535–3542.

    Article  CAS  Google Scholar 

  56. Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K et al. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2010; 16: 1419–1427.

    Article  Google Scholar 

  57. Fenske TS, Carreras J, Zhang M, Laport G, Montoto S, Maloney D et al. Outcome of patients with mantle cell lymphoma undergoing autologous versus reduced-intensity allogeneic transplantation. Ann Oncol 2011; 22: iv87.

    Google Scholar 

  58. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the cibmtr. Biol Blood Marrow Transplant 2013; 19: 625–631.

    Article  Google Scholar 

  59. Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C et al. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Bone Marrow Transplant 1999; 24: 473–481.

    Article  CAS  Google Scholar 

  60. Weisdorf DJ, Verfaille CM, Miller WJ, Blazar BR, Perry E, Shu XO et al. Autologous bone marrow versus non-mobilized peripheral blood stem cell transplantation for lymphoid malignancies: a prospective, comparative trial. Am J Hematol 1997; 54: 202–208.

    Article  CAS  Google Scholar 

  61. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009; 27: 4365–4370.

    Article  CAS  Google Scholar 

  62. Brody JD, Goldstein MJ, Czerwinski DK, Levy R . Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood 2009; 113: 85–94.

    Article  CAS  Google Scholar 

  63. Holman PR, Costello C, deMagalhaes-Silverman M, Corringham S, Castro J, Ball ED . Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2012; 18: 257–264.

    Article  Google Scholar 

  64. Porter DL, Levine BL, Kalos M, Bagg A, June CH . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725–733.

    Article  CAS  Google Scholar 

  65. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009; 23: 1716–1730.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology and Oncology, West Virginia University, Morgantown, WV, USA

    L Chaudhary & M Hamadani

  2. Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute and University of South Florida College of Medicine, Tampa, FL, USA

    M A Kharfan-Dabaja

  3. Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

    P Hari

  4. Myeloma and Lymphoma Service, Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA

    M Hamadani

Authors
  1. L Chaudhary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M A Kharfan-Dabaja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Hari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Hamadani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Hamadani.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaudhary, L., Kharfan-Dabaja, M., Hari, P. et al. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?. Bone Marrow Transplant 48, 1489–1496 (2013). https://doi.org/10.1038/bmt.2013.56

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.56

Keywords

This article is cited by

Search

Advanced search

Quick links